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AbstrAct
Introduction Global developmental delay (GDD) 
affects 1%–3% of the population of children under 
5 years of age, making it one of the most common 
conditions presenting in paediatric clinics; causes 
are exogenous, genetic (non-metabolic) or genetic 
(metabolic). Recent advances in biotechnology and 
genetic testing mean that the investigations available 
to perform for children under 5 years are increasing 
and are more sensitive than previously. This change in 
availability and type of testing necessitates an update in 
the recommendations for investigating GDD.
Methods We conducted a review of the literature from 
2006 to 2016 to identify articles with evidence relating 
to the investigation of developmental delay in children 
under the age of 5 years. We collated the evidence into 
first-line and second-line investigations and, where 
available, on their yield and cost implications.
results We have provided up-to-date guidance for 
first-line and second-line investigations for children 
with GDD under the age of 5 years. Recent evidence 
demonstrates that genetic testing for all children with 
unexplained GDD should be first line, if an exogenous 
cause is not already established. Our review of the 
literature demonstrates that all patients, irrespective of 
severity of GDD, should have investigations for treatable 
conditions. Evidence demonstrates that the yield for 
treatable conditions is higher than previously thought 
and that investigations for these metabolic conditions 
should be considered as first line. Additional second-line 
investigations can be led by history, examination and 
developmental trajectories.
Discussion We may need to update present 
recommendations in the UK for investigation of 
developmental delay. This would include microarray 
testing as first line and a more thorough approach 
to investigations for metabolic disorders that can be 
treated. Clinical assessment remains vital for guiding 
investigations.
IntroDuctIon
Global developmental delay (GDD) is defined as 
a delay in two or more developmental domains of 
gross/fine motor, speech/language, cognition, social/
personal and activities of daily living, affecting 
children under the age of 5 years.1 2 The degree of 
developmental delay is further subclassified as: mild 
(functional age <33% below chronological age), 
moderate (functional age 34%–66% of chrono-
logical age) and severe (functional age <66% of 
chronological age).1 GDD is considered significant 
when there is a deficit in performance of at least 
2 SD below the age appropriate mean on accepted 
standardised assessment tests.3 With a prevalence 
of 1%–3%, GDD is one of the the most common 
conditions encountered in paediatrics with genetic 
and structural brain abnormalities being the most 
frequent causes.1 Establishing a diagnosis enables 
clinicians to define treatment options and conduct 
surveillance for known complications as well as 
provide prognosis and condition-specific family 
support (including family planning choices). This 
ensures the best overall outcomes for the child and 
their families/carers.4 A diagnosis may also provide 
an explanation, a source of closure or acceptance 
to parents and stops clinicians advancing to poten-
tially more expensive and invasive tests5–7 
Previous estimates for the yield of investigations 
for GDD are broad (10%–81%).2 The variability 
may be due to differences in patient populations, 
clinical settings where tests are performed and 
the range of tests undertaken.2The last evidence-
based UK guideline for investigation of develop-
mental delay was published 10 years ago.8 With 
the advent of more recent techniques in genetics 
and a recent burgeoning of guidelines in other 
countries,4 9 10 there is a need to review our prac-
tice in the UK.
The primary objective of this paper is to provide 
(1) an update of the latest evidence for investigation 
of GDD, (2) recommendations for investigations 
and (3) evidence relating to yield and cost from 
literature presently available.
MethoDs
We conducted a systematic review of the literature 
relating to the investigation of GDD published in 
the last 10 years (since the McDonald review in 
2006). We searched Pubmed, Google Scholar and 
Embase using the MESH terms: ‘developmental 
delay’, ‘developmental disorders’, ‘mental retarda-
tion’, ‘intellectual disability’, ‘learning disorders’ 
AND ‘guidelines’ AND ‘investigations’. ‘Cost’ and 
‘yield’ were included along with the MESH terms. 
Papers included were reviews, consensus recom-
mendations, retrospective or prospective studies. 
Relevant articles from reference lists were also 
included. We included papers published in English 
that were relevant to children that included investi-
gations for GDD. We excluded papers that targeted 
specific metabolic, genetic or neurological condi-
tions. We used the term GDD as meaning: delayed 
developmental domains in children under the age 
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of 5 years and intellectual disability (ID) as the term used after 
this age when IQ can be reliably tested.11
For this review, we discuss and categorise investigations 
into first-line and second-line tests and subcategorised them to 
genetics, metabolic and imaging. See table 1 for recommended 
first-line investigations to be considered prior to referral to 
specialist services. We show a flowchart and decision-making 
tree for investigations in figure 1.
FIrst-lIne AssessMent AnD InvestIgAtIons
history and examination
Comprehensive clinical assessment remains the core to plan-
ning investigations in young children presenting with GDD.4 8–10 
Aetiology can be categorised into exogenous, genetic (non-met-
abolic) and genetic (metabolic).11 The diagnosis of exogenous 
causes includes teratogenic agents (alcohol and drugs); prenatal, 
perinatal causes (prematurity, infections); and social causes often 
best assessed by history but must not be assumed.
Investigations following a thorough clinical history (including 
a family pedigree, pregnancy and birth history) and a detailed 
physical examination by a trained specialist lead to a higher diag-
nostic yield.3 12 Identification and correction of sensory deficits 
are essential, while evaluating these children and may provide 
pointers to the underlying aetiology.2 6
An examination of the child’s developmental status in all 
domains (gross motor, fine motor, language, socioemotional and 
cognitive skills) using a recognised tool to provide a normative 
comparison should also be conducted. Repeated clinical/dysmor-
phology and developmental assessments over time are more 
informative than one-off assessments in planning investigations 
and management.
It is important that the clinician consider investigations in all 
levels of developmental delay including those with persistent 
mild GDD, given the variable phenotypic presentations of 
genetic and metabolic conditions. Some studies, although 
from tertiary centres, have found that severity did not impact 
on the diagnostic rate of investigations,12 while others report 
higher yield in patients with moderate-to-severe GDD.13 Serial 
assessment enables clinicians to identify changing phenotypes 
over time. When metabolic conditions are clinically suspected, 
annual evaluation after the first year of life until school age is 
recommended.14
Some studies have demonstrated that we can identify the 
cause of developmental or cognitive delay in a one-third of 
cases by history and examination alone. With clinical evaluation 
prompting investigations, we can identify another one-third. 
It is only the latter one-third that are identified by investiga-
tions only.12 The presence of abnormal neurology, microcephaly, 
female gender, dysmorphism, abnormal prenatal or perinatal 
history and absence of autistic features are linked with higher 
aetiological yield of investigations.15 Investigations following 
comprehensive clinical evaluation are also cost effective.16
table 1 Table demonstrating recommendations for first-line investigations for global developmental delay from four guidelines and our proposed 
recommendations 
tests category
uK current
McDonald et al8 uK proposed
usA
Moeschler and shevell4
Irish
o'byrne et al10
Australian
silove et al9
Genetic Karyotype
Frag X
Microarray
Frag X (selected)
Microarray
Frag X
Microarray
Frag X (selected)
Chromosomal: banded analysis 
(selected)
Microarray
Frag X
Biochemical and metabolic
Blood tests U&E
CK
TFT
Lead
Urate
FBC
Ferritin
Biotinidase
U&E
CK
TFT
Lead (If PICA)
FBC
Ferritin (dietary restriction)
AA
Homocysteine
Acylcarnitine profile
TFT
Lead (selected)
AA
Homocysteine
Acylcarnitine profile
U&E
CK
TFT
LFT
FBC
Bone profile
Urate
Glucose, lactate
Venous blood gas
AA
Homocysteine
(selected if raised methionine)
U&E
CK
TFT
FBC
Lead
AA
Urine tests OA
GAG
Oligosaccharides
Creatine/GAA
Purine and pyramidines
OA
GAG
Oligosaccharides
Creatine/GAA
Purine and pyramidines
OA
GAG
Paired urate
+Urate/creatinine
OA
GAG
AA, amino acids; ASD, autistic spectrum disorder; CK, creatine kinase; FBC, full blood count; Frag X, fragile X; GAG, glycosaminoglycans; LFT, liver function test; OA, organic 
acids; TFT, thyroid function tests; U&E, urea and electrolytes.
Figure 1 Flow chart for decision making for investigations for global 
developmental delay in young children.
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genetic testing
First-line tests 
Genetic investigation by means of standard karyotyping was 
recommended as a first-line investigation in the UK guidance 
from 2006.8 The implementation of ‘molecular karyotyping’ 
or chromosome microarray (array-based comparative genomic 
hybridisation (aCGH)) has changed the state of play. Recent 
evidence-based international guidelines promote the use of 
aCGH as a first-tier investigation for GDD if no aetiological 
indicators from history and examination are found.4 9 10 The 
higher sensitivity that it has for identifying submicroscopic dele-
tions and duplications (than standard karyotyping methods) and 
better definition of the breakpoints and size of imbalances all 
make microarray a suitable first-line test.4 17 18
Chromosome microarray has been described to be the ‘single 
most efficient diagnostic test’ for GDD after history and exam-
ination.4 A literature search of 33 studies that used this technique 
in nearly 22 000 patients has demonstrated that the diagnostic 
yield of aCGH is between 15% and 20%, while karyotyping is 
3%.18 The diagnostic yield of microarray is supported by a health 
economics report, which showed cost saving when comparing a 
National Health Service (NHS) clinical genetics service use of 
aCGH as a first-tier test while evaluating learning disability, 
compared with CGH as second line after negative karyotyping.19
Molecular karyotyping will not detect conditions where struc-
tural changes in the chromosomes result in no loss or gain of 
genetic material such as balanced translocations or inversions, 
ring chromosomes and low-level mosaicism.18 20 A standard 
karyotype is still required if such a disorder is suspected (eg, 
refractory epilepsy, if a family is known to have a balanced 
translocation associated with a phenotype, a history of 
multiple miscarriages or clinical features to suggest mosaicism). 
Syndromes caused by methylation defects (eg, Beckwith-Wiede-
mann, Angelman syndrome) or mutations in single genes will 
also go undetected unless specifically tested.
Fragile X syndrome affects approximately 1/5000 births, typi-
cally causing moderate ID in boys and a variable phenotype in 
girls (unaffected to significant). Phenotypic features evolve and 
are not as apparent in younger children.9 The UK genetic testing 
network and international guidelines therefore do promote 
testing for fragile X for children with moderate-to-severe GDD, 
without profound physical disability, as an additional first-tier 
genetic investigation.4 9 10 21 Testing criteria are available to help 
aid clinical decisions in older children.21
Second-line tests
Clinical syndromes can present with variable phenotypes, and 
children who have a normal aCGH and FMR1 may be best 
assessed by a clinical geneticist to ensure that the most appro-
priate and cost-effective additional tests are undertaken.22 Use of 
specific gene tests such as those for Rett syndrome (or its variants) 
or gene panels for ID has been proposed as second-line tests.4 
There is an increasing number of panels and exome sequencing 
tests available for ID (UK Genetic Testing Network; http://www. 
ukgtn. nhs. uk) or private providers, but specialist services (clin-
ical genetics or paediatric neurology) do most requests for these 
tests, although this is likely to change as mainstreaming of these 
investigations advances.
Metabolic and biochemical investigations
There is limited good quality evidence for first-line metabolic 
investigations. Recommendations from Ireland are based on 
evidence review by expert committee,10 while those from 
Australia are based on a literature review, quoting grade III–IV 
evidence.9
Inborn errors of metabolism (IEMs) are rare, their prevalence 
likely to vary in different populations. There is limited UK data 
on detecting metabolic disorders in patients with GDD.14 IEMs 
are usually associated with systemic features, and previous guide-
lines recommend selective metabolic investigations.2 8 Some IEMs 
are now (partially) treatable, and for others, treatment is in the 
research stages. Treatment includes dietary supplements (folinic 
acid for cerebral folate deficiency, pyridoxine or pyridoxal phos-
phate for B6-responsive epilepsy, creatine in creatine transporter 
deficiency, uridine in pyrimidine 5-nucleotidase super activity), 
dietary restriction (homocystinuria, glutaricacidaemia) and keto-
genic diet (pyruvate dehydrogenase deficiency, Glut1 transporter 
deficiency). Other treatments include: haematopoietic stem 
cell transplantation (mucopolysaccharidoses, metachromatic 
leucodystrophy), enzyme replacement (Fabry’s disease, Gauch-
er's disease, neuronal ceroid lipofuscinosis) or gene therapy 
(adrenoleucodystophy, lysosomal storage disorders).23–25
A systematic review of literature by van Karnebeek et al iden-
tified 89 conditions presenting with ID as a major feature, which 
are susceptible to treatment. Of these, 60% could be identified by 
non-targeted urine and blood tests. Some of these conditions (eg, 
creatine transporter defects, mild homocystinuria, female orni-
thine transcarbamylase deficiency) can initially present as GDD 
alone.25 26 While individual treatable IEMs are extremely rare 
in the general population, the prevalence will be higher in the 
at-risk population. Hence, though small in number, these treat-
able causes of GDD have been the focus of the more recent US 
guidance, with recommendations that screening for IEM should 
be used in all patients with GDD of unknown aetiology.4 24 A 
list of tests with treatable conditions they identify is shown in 
table 2.
The neonatal screening programme in the UK (Guthrie test) 
currently includes six IEMs (phenyketonuria, medium-chain 
acyl-CoA dehydrogenase deficiency, maple syrup urine disease, 
isovaleric acidaemia, glutaricaciduria type 1, homocystinuria 
(pyridoxine unresponsive)) and congenital hypothyroidism. It 
is restricted when compared with other countries (eg, Canada, 
the USA, The Netherlands), which offer a wider range including 
urea cycle disorders, organic and some amino acid disorders. 
Testing for these is, therefore, more relevant in UK patients with 
GDD, and IEMs should be considered in symptomatic children.14
There are also some conditions where early diagnosis can be 
made from simple and cheap biochemical screening tests. This 
includes creatine kinase and thyroid function tests as well as 
ferritin, vitamin B12 and lead on a selective basis when Pica, 
dietary restrictions (vegan diet in child/mother) or environ-
mental exposure risk is possible.9 While these tests seldom lead 
to a diagnosis, they also may add to a diagnosis (eg, macrocytic 
anaemia in organic acidaemias, abnormal triiodothyronine in 
Allan-Herdon-Dudley syndrome).10 27
There is limited research on comprehensive metabolic evalu-
ation in larger groups of individuals with GDD. It is, therefore, 
difficult to estimate the yield of many of the proposed first-line 
metabolic tests. A recent systematic review conducted for the 
American Academy of Neurology found that yield of metabolic 
investigations varied between 0.2% and 4.6%, based on clin-
ical signs and range of tests undertaken in the studies (grade III 
evidence).28 Second-line individually tailored testing in a tertiary 
setting in the Netherlands produced an overall yield of 2.8% for 
metabolic investigations.11
Individually tailored second-line testing4 14 26 and referral to 
a specialist service is recommended,4 9 when clinical suspicion 
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remains. An evidence-based, free web-based application (http://
www. treatable- id. org) may be useful to tailor investigations for 
treatable IEMs not covered by first-line tests.29
neuroimaging
MRI of the brain has been used selectively and non-selectively 
in evaluating patients with GDD. The diagnostic yield of MRI is 
higher when used in patients where GDD is associated with clin-
ical signs such as abnormal head circumference (microcephaly, 
non-familial macrocephaly, rapid change in head circumfer-
ence), focal neurological signs or epilepsy. Targeted imaging was 
hence advocated by previous guidelines.2 8 Previous studies have 
demonstrated abnormal results in targeted imaging in about 
41% compared with 14% with non-selective screening.3 Recent 
studies continue to demonstrate higher abnormality detection 
rates when MRI is performed in patients with GDD with addi-
tional clinical/neurological signs.30 31 More complex MRI proto-
cols (eg, proton magnetic resonance spectroscopy) are promising 
tools to investigate GDD and enable a non-invasive measure 
of brain metabolites such as lactate or white matter choline,32 
but studies have so far failed to show an increased diagnostic 
yield,31 33 and hence these are best used as second line in selected 
patients.
MRI is a more sensitive test and has no radiation exposure, 
making it a preferred choice over CT. However, all children 
under 5 years will need sedation or a general anaesthetic, which 
has a slim risk attached, and some children will need further 
investigations including a lumbar puncture. There is an argu-
ment, therefore, that children requiring brain imaging should see 
a specialist prior to imaging, if an anaesthetic is required.
special considerations
Regression
A child where there is concern about regression in skills should 
be referred for an assessment from a specialist in neurodisability 
or neurology. True regression is quite rare, but incidence can vary 
with ethnic background of the local population. It can be diffi-
cult to establish if there is true regression or if the child has an 
evolution of their static disorder. Sometimes a child with GDD 
can demonstrate pseudo-regression where the gap in intellectual 
abilities between them and their peers is widening or in a child 
with cerebral palsy (CP) who has rapid growth and who may 
experience a decline in the motor function. The development of 
epilepsy can also impact on cognitive or behavioural function, 
especially in those with pre-existing GDD, autistic spectrum 
disorder or CP. Some children with regression may have a step-
wise deterioration in function associated with decompensation 
(often an encephalopathy). This clinical pattern points to energy 
failure, and mitochondrial disorders should be suspected. A full 
discussion about genuine regression is beyond the scope of this 
article. However, the recent progressive intellectual and neuro-
logical deterioration study (www. rcpch. ac. uk/ pind) has provided 
excellent data about more common causes (box).34 Some disor-
ders that cause regression may be amenable to treatment or be 
eligible for a treatment trial. It is important, therefore, that the 
general paediatrician should have an awareness of the presenta-
tion of these disorders.
Children that should be referred to a specialist in neurodis-
ability or neurology are shown on table 3. Investigations should 
box ten most common causes of progressive intellectual 
and neurological deterioration
 ► 10 most common causes of PIND reported in the PIND study 
in the UK (www.rcpch.ac.uk/pind)34
 ► NCL late infantile
 ► Mucopolysaccharidosis IIIA (San Filippo)
 ► Rett syndrome
 ► Metachromatic leucodystrophy
 ► Adrenoleucodystrophy
 ► NCL juvenile
 ► GM2 gangliosidosis type 1 (Tay-Sachs)
 ► Niemann-Pick type C
 ► Krabbe
 ► GM2 gangliosidosis type 2 (Sandhoff)
NCL, neuronal ceroid lipofuscinosis; PIND, progressive intellectual and 
neurological deterioration.
table 2 Table demonstrating IEM tested for by first-line metabolic 
investigations25
test
(number of conditions 
identified) conditions identified
Plasma amino acids, n=13 l.o. argininemia, l.o. argininosuccinic aciduria
l.o. citrullinemia , l.o. citrullinemia type II
CPS deficiency, HHH syndrome
Maple syrup urine disease (variant)
l.o. NAGS deficiency, OTC deficiency
Phenylketonuria, tyrosinemia type II
MTHFR deficiency, PDH complex deficiency
Plasma total homocysteine, n=7 Cobalamin C, D, E, F and G deficiencies
Homocystinuria, MTHFR deficiency
Acylcarnitine, n=7 Ethylmalonic encephalopathy
Isovaleric acidemia, tyrosinemia type II
Cobalamin C, D and F deficiencies, 
3-methylcrotonyl glycinuria
Urine organic acid, n=22 β-Ketothiolase deficiency, MHBD deficiency
Cobalamin A, B, C, D and F deficiencies
Glutaric acidemia I, glutaric acidemia II
HMG-CoA lyase deficiency, tyrosinemia type II
Holocarboxylase synthetase deficiency
3-Methylglutaconic aciduria, 3-methylylcrotonyl 
glyciuria
Methylmalonic acidemia, isovaleric acidemia
Homocystinuria, propionic acidemia mHMG-CoA 
synthase deficiency
SCOT deficiency, SSADH deficiency
Glycosaminoglycans, n=4 Hunter syndrome (MPS II)
Hurler syndrome (MPS I)
Sanfilippo syndrome A, B, C
Sly syndrome (MPS VII)
Purines and pyramidines, n=3 Molybdenum cofactor deficiency type A
Pyrimidine 5-nucleotidase superactivity
Lesch-Nyhan syndrome
Oligosaccharides, n=2 α-Mannosidosis
Aspartylglucosaminuria
Urine creatine metabolites, n=3 AGAT deficiency
Creatine transporter defect
GAMT deficiency
Adapted from Van Karnebeek.25 Some conditions are identified by more than one 
test.
AGAT, arginine: glycine amidinotransferase; CPS, carbamoyl phosphate synthetase; 
GAMT, guanidino-acetate-N-methyltransferase; HHH, hyperornithinemia, 
hyperammonemia, homocitrullinemia; HMG-CoA, 3-hydroxy-3-methylglutaryl-
CoA; l.o., late-onset form; MHBD, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase; 
mHMG CoA, mitochondrial 3-hydroxy-3-methylglutaryl-CoA; MTHFR, 
methylenetetrahydrofolate reductase; NAGS, N-acetylglutamate synthetase; OTC, 
ornithine transcarbamylase; PDH, pyruvate dehydrogenase; SCOT, succinyl CoA 
3-oxoacid CoA transferase; SSADH, succinic semialdehyde dehydrogenase.
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table 3 Clinical pointers to consider referral to a specialist in neurodisability or neurology
Features in the history Regression or possible regression including significant change in behaviour
Possible or definite seizures
Movement disorder: continuous or paroxysmal
Muscle pain/fatigue
New onset sensory impairment, for example, significant decline in visual acuity
Cognitive decline/behavioural change in a child with epilepsy or ASD
Examination findings Neurological signs: dystonia, ataxia, movement disorder, for example, chorea, focal signs, cranial nerve signs, muscle weakness/signs of a peripheral 
neuropathy, arthrogryposis/joint contractures, CP picture without a clear cause/history
Ocular signs: nystagmus, eye movement disorder, abnormal fundi, cataract
Other signs: sensorineural deafness
Neurocutaneous features
Organomegaly/cardiomegaly
Course or dysmorphic facial features
CP, cerebral palsy.
be individualised and targeted as they can be invasive (eg, LP, 
muscle/skin biopsy) or painful (eg, nerve conduction studies and 
electromyography) and are expensive and time consuming for 
medical staff and families. Children with regression may also be 
referred to the clinical genetics team where specific next-gen-
eration sequencing panels can be undertaken and, at present, 
considered for the 100 000 Genome Project (www. genomicsen-
gland. co. uk/ the- 100000- genomes- project).
Immigrant children
Immigrant children are exposed to a combination of biolog-
ical, socioeconomical, emotional and environmental adverse 
events placing them at higher risk of developmental problems. 
This includes malnutrition and disability from trauma, over-
crowding and toxin exposure and loss of parents or trauma 
from lack of stability.35 Furthermore, children may have missed 
new-born screens and vaccinations and been exposed to infec-
tious diseases. In these children, comprehensive clinical assess-
ments should consider all these factors while planning individual 
investigations.
DIscussIon
Despite new advances in technology, particularly in the realm 
of genetic investigation, clinical assessment continues to be vital 
in guiding investigation. Clues to investigation may lie in the 
history and examination with clinical judgement being essential 
to enabling the right pathways to be taken in making a diagnosis. 
A good history can help direct which route to take in terms of 
investigation, particularly when exogenous causes are identified. 
Assessment over a period will provide clarity as to whether a 
condition is resolving, static or deteriorating. Assessment over 
time enables the phenotype to evolve and more appropriate 
targeting of investigations.
It is clear that establishing a diagnosis enables us to answer 
questions on: why it has happened (aetiology), what does it 
mean for our child (prognosis), what treatments might be avail-
able (precision medicine) and whether it can be prevented in the 
future (prenatal testing and preimplantation genetic diagnosis).
In these recommendations, we have also highlighted the recent 
evidence that promotes metabolic screening tests to detect treat-
able conditions. This is a move away from older guidance where 
metabolic investigations were not recommended for children 
with no features/risk factors other than GDD.2 Though rare, 
the possibility of presentation as stable developmental delay and 
potential for treatment merits their inclusion as first-line tests. 
Treatment outcomes vary but can potentially improve cognitive 
development, slow deterioration, prevent metabolic decom-
pensation and improve seizure control and systemic manifesta-
tions.25 26
GDD and ID affect 2%–3% of the worldwide population with 
a lifetime cost of up to US$1 million.36 First-line metabolic inves-
tigations to identify treatable IEMs cost approximately $C568,26 
with costs in Ireland for all first-line tests at €1335.10 Costs in 
the UK NHS laboratory for aCGH are not astronomical (£338–
£350),37 38 with the majority of combined metabolic tests costing 
under £1000.38 Not all children will get a diagnosis and cost 
per diagnosis may be high, but there are obvious long-term cost 
savings if early diagnosis and treatment are possible. The options 
of genetic counselling and support for young families also make 
diagnosis invaluable.
Recent advances in genomic medicine are transforming the 
investigation of children with significant developmental delay 
and are likely to transform the way we assess and investigate 
children. Traditional models of care have relied on history and 
examination with broad and then specific investigations to 
funnel down to specific diagnoses. The advent of rapid genetic 
testing and ‘omic’ medicine is likely to turn this paradigm on its 
head with whole genome/exome sequencing identifying genes, 
which may be causing the phenotype in an individual. The clini-
cian will then use knowledge of their patient to make a judge-
ment about whether this is the cause for their patient—‘reverse 
dysmorphology’.
These advances in genomic medicine will lead to an increase in 
diagnoses that will modify how the individual is clinically cared 
for (precision medicine). The Deciphering Developmental Disor-
ders study and the 100 000 Genome Project will both aid our 
understanding of disorders. We predict that, with time, whole 
genome sequencing/exome sequencing may become the first-line 
investigation of choice for all children with unexplained GDD 
and that other investigations will be secondary to this and used 
primarily for phenotyping. These will provide answers for fami-
lies about the underlying cause of their child’s condition and will 
prevent further costly and potentially distressing investigations 
taking place.
conclusIons
In this paper, we have outlined the present evidence and recom-
mendations for both first-line and second-line investigations for 
GDD in children in the UK. We have provided new evidence 
relating to the use of genetic testing techniques and have 
demonstrated that this should be a first-line investigation for 
all children with GDD. Second to this, any treatable metabolic 
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conditions should be always considered. With time, it is likely 
that the investigation of children with developmental delay will 
be turned on its head and we will be going from genetic diag-
nosis to phenotypic diagnosis. Despite this, history and exam-
ination will always be crucial for defining the condition and the 
change over time.
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